FTC on ephedra
This article was originally published in The Tan Sheet
FTC considers claims ephedra products are safe to be misleading and "we can and do go to federal court in order to stop" them, Bureau of Consumer Protection Director Howard Beales tells House Government Reform Committee March 27 during Internet pharmacy hearing. In response to question from Rep. Henry Waxman (D-Calif.), Beales states FTC has filed "four cases so far going back to 1997 challeng[ing] claims that ephedra was safe or had no side effects as unsubstantiated." He notes all four cases were decided in FTC's favor and that "we have other investigations involving ephedra products and there will be more cases that are in the pipeline"...
You may also be interested in...
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.